|1.||Kitano, K: 2 articles (08/2002 - 01/2000)|
|2.||Makioka, A: 2 articles (07/2001 - 04/2001)|
|3.||Kobayashi, S: 2 articles (07/2001 - 04/2001)|
|4.||Kumagai, M: 2 articles (07/2001 - 04/2001)|
|5.||Ohtomo, H: 2 articles (07/2001 - 04/2001)|
|6.||Takeuchi, T: 2 articles (07/2001 - 04/2001)|
|7.||Shankar, Jay: 1 article (01/2015)|
|8.||Nabi, Ivan R: 1 article (01/2015)|
|9.||Wong, Victoria: 1 article (11/2014)|
|10.||Wellington, Karie: 1 article (11/2014)|
|1.||Lewis Lung Carcinoma
01/01/1998 - "Jasplakinolide was a radiation sensitizer in the Lewis lung carcinoma. "
01/01/1998 - "Jasplakinolide was also effective against the systemic Lewis lung carcinoma, decreasing lung metastases. "
01/01/1998 - "In vivo, jasplakinolide was an active antitumor agent against the Lewis lung carcinoma and the DU-145 prostate carcinoma xenograft. "
01/01/1998 - "The response of human PC-3 and DU-145 prostate carcinoma cells and DU-145 xenografts and the response of the Lewis lung carcinoma to jasplakinolide were studied. "
01/01/1998 - "Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma."
|2.||Pemphigus (Pemphigus Vulgaris)
09/01/2010 - "Therefore, we investigated whether pharmacological manipulation of actin polymerization modulates pathogenic effects of PV-IgG. Pharmacological stabilization of actin filaments via jasplakinolide significantly blocked cell dissociation and Dsg3 fragmentation, whereas cytochalasin D-induced actin depolymerization strongly enhanced pathogenic effects of PV-IgG. To substantiate these findings, we studied whether the protective effects of Rho GTPases, which are potent regulators of the actin cytoskeleton and were shown to be involved in pemphigus pathogenesis, were dependent on modulation of actin dynamics. "
|3.||Neoplasm Metastasis (Metastasis)
01/01/1998 - "In the DU-145 tumor, the effects of jasplakinolide and fractionated radiation for 1 or 2 weeks appeared to be primarily additive. "
01/01/1998 - "Lung metastases were further decreased when jasplakinolide was administered along with radiation to the subcutaneous primary tumor. "
11/01/2014 - "Therefore, the present study sought to determine the tolerated in vivo doses of cytochalasins and jasplakinolide in zebrafish (Danio rerio), a well-studied fish cancer model that is 1.5% the size of mice. "
11/01/2014 - "Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo."
04/01/2014 - "With one exception, annulated indoles inhibited the metabolic activity of HL-60 tumor cells in the low-micromolar range after two and four days in culture but these anti-proliferative effects were weaker than those of jasplakinolide, a known actin binder that blocks cytokinesis. "
10/21/1998 - "The chondramides--unlike jasplakinolide--can be produced in large amounts by fermentation, and, similar to jasplakinolide, they appear to have antiproliferative activity against carcinoma cell lines by targeting the actin cytoskeleton."
01/01/1998 - "Jasplakinolide was cytotoxic toward human prostate carcinoma cells, DU-145, PC-3 and LNCaP in culture, killing 1 log of cells with 0.8, 0.3 and 0.07 microM of drug in 24 h, respectively. "
01/04/1995 - "Jasplakinolide represents a novel marine natural product with potent in vitro antiproliferative activity against human prostate carcinoma cell lines, and it appears to target the actin cytoskeleton. "
01/04/1995 - "The effects of jasplakinolide on the proliferation of three human immortalized prostate carcinoma cell lines (PC-3, LNCaP, and TSU-Pr1) were studied. "
01/04/1995 - "Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton."
|2.||rho GTP-Binding Proteins (rho GTP-Binding Protein)
|3.||Immunoglobulin G (IgG)
|4.||Actins (F Actin)
|8.||latrunculin A (LAT-A)
|1.||Heterologous Transplantation (Xenotransplantation)